Photo of Debra Tonetti

Debra Tonetti


Professor of Pharmacology, College of Pharmacy - Pharmaceutical Sciences
Interim Head, College of Pharmacy - Pharmaceutical Sciences

Related Sites:

Teaching and Supervision

PDAT 9: Hematology/Oncology (PHAR 509), 1/11/2021 – 4/30/2021
PDAT 9: Hematology/Oncology (PHAR 509), 1/11/2021 – 4/30/2021
PDAT 9: Hematology/Oncology (PHAR 509), 1/11/2021 – 4/30/2021
PDAT 9: Hematology/Oncology (PHAR 509), 1/11/2021 – 4/30/2021
PDAT 9: Hematology/Oncology (PHAR 509), 1/13/2020 – 5/1/2020
Biopharmaceutical Sci II (BPS 502), 1/13/2020 – 5/1/2020
PDAT 9: Hematology/Oncology (PHAR 509), 1/13/2020 – 5/1/2020
PDAT 9: Hematology/Oncology (PHAR 509), 1/13/2020 – 5/1/2020
PDAT 9: Hematology/Oncology (PHAR 509), 1/13/2020 – 5/1/2020

Selected Grants

Breast cancer virotherapy, National Institutes of Health (National Cancer Institute)., 4/1/2021 - 3/31/2023, Obligated Amount: $186883; Anticipated Amount: $411143

Targeting Serine Auxotrophy in Luminal Breast Cancer, National Institutes of Health (National Cancer Institute)., 3/1/2021 - 2/28/2026, Obligated Amount: $359689; Anticipated Amount: $1798445

A Novel Biomarker for TTC-352 Therapy Development., 5/15/2019 - 4/30/2020, Obligated Amount: $1000000; No Anticipated Amount Set

A novel biomarker for TTC 352 cancer therapy development, University of Illinois DPI Seed Funding Program., 5/1/2019 - 4/30/2020, No Obligated Amount Set; Anticipated Amount: $100000

A Novel BET Inhibitor for Breast Cancer Combinatiion Therapy, Chicago Biomedical Consortium., 1/1/2019 - 12/31/2019, Obligated Amount: $100000; Anticipated Amount: $100000

Development of PET Probe for ER+ Breast Cancer, UICentre-CCTS Inception Grant., 7/1/2018 - 6/30/2019, No Obligated Amount Set; Anticipated Amount: $12500

Discovery of New Partners for Combination Therapy with G1T48, G1 Therapeutics Inc., 6/1/2017 - 5/31/2018, Obligated Amount: $350000; Anticipated Amount: $350000

Developing Nano Technology for HER2 Directed Therapy, National Institutes of Health (National Cancer Institute)., 3/1/2017 - 2/28/2022, Obligated Amount: $2756560; Anticipated Amount: $2958936

UIC Center for Population Health and Health Disparities - Research Supplement to Promote Diversity in Health Related Research, National Institutes of Health (National Cancer Institute)., 7/1/2016 - 6/30/2017, Obligated Amount: $500000; Anticipated Amount: $500000

Selected Publications

Means-Powell, Julie A, Mayer, Ingrid A, Ismail-Khan, Roohi, Del Valle, Luis, Tonetti, Debra, Abramson, Vandana G, Sanders, Melinda S, Lush, Richard M, Sorrentino, Claudia, Majumder, Samarpan, Miele, Lucio. (2021). A Phase Ib Dose Escalation Trial of RO4929097 (a γ-secretase inhibitor) in Combination with Exemestane in Patients with ER + Metastatic Breast Cancer (MBC). Clinical Breast Cancer. doi:10.1016/j.clbc.2021.10.013.

Abderrahman, B, Maximov, PY, Curpan, RF, Fanning, SW, Hanspal, JS, Fan, P, Foulds, CE, Chen, Y, Malovannaya, A, Jain, A, Xiong, R, Greene, GL, Tonetti, DA, Thatcher, GRJ, Jordan, VC. (2021). Rapid induction of the unfolded protein response and apoptosis by estrogen mimic ttc-352 for the treatment of endocrine-resistant breast cancer. Molecular Cancer Therapeutics, 20, (1), 11-25. doi:10.1158/1535-7163.MCT-20-0563.

Abderrahman, B, Maximov, PY, Curpan, RF, Hanspal, JS, Fan, P, Xiong, R, Tonetti, DA, Thatcher, GRJ, Jordan, VC. (2020). Erratum: Pharmacology and molecular mechanisms of clinically relevant estrogen estetrol and estrogen mimic BMI-135 for the treatment of endocrine-resistant breast cancer (Molecular Pharmacology (2020) 98 (364-381) DOI: 10.1124/molpharm.120.000054). Molecular Pharmacology, 98, (4), 528. doi:10.1124/molpharm.120.000054err.

Dudek, AZ, Liu, LC, Fischer, JH, Wiley, EL, Sachdev, JC, Bleeker, J, Hurley, RW, Tonetti, DA, Thatcher, GRJ, Venuti, RP, O’Regan, RM. (2020). Phase 1 study of TTC-352 in patients with metastatic breast cancer progressing on endocrine and CDK4/6 inhibitor therapy. Breast Cancer Research and Treatment, 183, (3), 617-627. doi:10.1007/s10549-020-05787-z.

Abderrahman, B, Maximov, PY, Curpan, RF, Hanspal, JS, Fan, P, Xiong, R, Tonetti, DA, Thatcher, GRJ, Jordan, VC. (2020). Pharmacology and Molecular Mechanisms of Clinically Relevant Estrogen Estetrol and Estrogen Mimic BMI-135 for the Treatment of Endocrine-Resistant Breast Cancer (vol 98, pg 364, 2020). MOLECULAR PHARMACOLOGY, 98, (4), 528-528.

Jordan, VC, MacGregor, JI, Tonetti, DA. (2020). Selective estrogen receptor modulators as a new postmenopausal prevention- maintenance therapy. Progress in the Management of the Menopause. (pp. 18-25). doi:10.1201/9781003076575-4.

Li, Y, Zhao, J, Gutgesell, LM, Shen, Z, Ratia, K, Dye, K, Dubrovskyi, O, Zhao, H, Huang, F, Tonetti, DA, Thatcher, GRJ, Xiong, R. (2020). Novel Pyrrolopyridone Bromodomain and Extra-Terminal Motif (BET) Inhibitors Effective in Endocrine-Resistant ER+ Breast Cancer with Acquired Resistance to Fulvestrant and Palbociclib. Journal of Medicinal Chemistry, 63, (13), 7186-7210. doi:10.1021/acs.jmedchem.0c00456.

Jordan, VC, MacGregor, JI, Tonetti, DA. (2020). Selective estrogen receptor modulators as a new postmenopausal prevention- maintenance therapy. Progress in the Management of the Menopause. (pp. 18-25). doi:10.4324/9781003076575-4.

Andreano, KJ, Wardell, SE, Baker, JG, Desautels, TK, Baldi, R, Chao, CA, Heetderks, KA, Bae, Y, Xiong, R, Tonetti, DA, Gutgesell, LM, Zhao, J, Sorrentino, JA, Thompson, DA, Bisi, JE, Strum, JC, Thatcher, GRJ, Norris, JD. (2020). G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer. Breast Cancer Research and Treatment, 180, (3), 635-646. doi:10.1007/s10549-020-05575-9.

Education

Degrees:
Doctor of Philosophy, Loyola University Chicago, United States, 1990
Master of Science, Loyola University Chicago, United States, 1985
Bachelor of Science, Northern Illinois University, United States, 1980

Postgraduate Training:
Enrico Fermi Postdoctoral Fellow, Argonne National Laboratory, United States, 1994